Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. August 2018 16:05 ET | Quelle: Zafgen, Inc.

Zafgen Announces Departure of President and Chief Scientific Officer Dr. Thomas Hughes

BOSTON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected...
01. August 2018 16:15 ET | Quelle: Zafgen, Inc.

Zafgen to Present at the Canaccord Genuity 38th Annual Growth Conference

BOSTON, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
31. Juli 2018 16:05 ET | Quelle: Zafgen, Inc.

Zafgen to Host Conference Call to Discuss Second Quarter 2018 Financial Results

BOSTON, July 31, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel...
09. Juli 2018 08:00 ET | Quelle: Zafgen, Inc.

Zafgen and the Foundation for Prader-Willi Research Announce PATH for PWS Natural History Study

Information and data from study will advance understanding of medical history and medical events in people with PWS People living with PWS ages 5 and older and their caregivers are encouraged to...
02. Juli 2018 16:05 ET | Quelle: Zafgen, Inc.

Zafgen Announces Closing of Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Common Shares

BOSTON, July 02, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for...
28. Juni 2018 08:00 ET | Quelle: Zafgen, Inc.

Zafgen Announces Pricing of Offering of Common Stock

BOSTON, June 28, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for...
27. Juni 2018 16:01 ET | Quelle: Zafgen, Inc.

Zafgen Announces Proposed Offering of Common Stock

BOSTON, June 27, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for...
25. Juni 2018 07:05 ET | Quelle: Zafgen, Inc.

Zafgen Set to Join Russell 3000® Index

BOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for...
25. Juni 2018 07:00 ET | Quelle: Zafgen, Inc.

REMINDER: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call

BOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc., (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected...
23. Juni 2018 10:00 ET | Quelle: Zafgen, Inc.

Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes

Trial met all primary objectives, demonstrated efficacy and safety and established minimally effective dose of 0.9 mg for ZGN-1061 Patient dosing recently initiated for the 1.8 mg dose cohort Zafgen...

Vorherige Seite

Nächste Seite